Information Provided By:
Fly News Breaks for July 10, 2015
CRL
Jul 10, 2015 | 05:34 EDT
Barclays analyst Douglas Tsao downgraded Charles River Laboratories to Underweight saying he sees greater downside risk at current valuation levels. The company's organic earnings power may be weaker than some expect amid secular challenges in vivo testing, the analyst tells investors. He keeps a $60 price target for shares.
News For CRL From the Last 2 Days
There are no results for your query CRL